Penns Woods Bancorp (NASDAQ:PWOD) reported quarterly earnings of $0.74 per share. This is a 27.59 percent increase over earnings of $0.58 per share from the same period last year.
AstraZeneca Announced Himalaya Phase III Trial Met Primary Endpoint of Survival in 1st-line Unresectable Liver Cancer
Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not